On the stock market since 2017, it operates in the world of health and science. It has 6 employees. Now — the numbers.
This is an established company with proven profits.
If every debt were paid off today, $14.0M would still be left in the vault — a solid cushion for hard times.
Buys outnumber sells, but taken together the trades don’t add up to a strong signal of confidence.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
The price is looking for direction — no strong breakout, no collapse.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
An investor who bought at the very peak is down 97% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The average analyst price target is $5.50 — 362% above today’s price.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 8/100.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 10/100.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 22/100.
On our five-subject report card, CYPH sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CYPH is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (10/100) says the stock isn’t cheap.